semaglutide liver damage Gets FDA Greenlight for MASH Semaglutide Showing Promise in Treating
Description
Oxyntomodulin has already shown to reduce food intake and bodyweight in rodents and humans ( In addition to GLP-1R/GCGR dual agonists, a chimeric peptide as dual GLP-1/GIP receptor agonists has been developed, showing enhanced therapeutic potential for obesity and related comorbidities
Celine Gounder explains what this means for patients
Kelly, M
After removing it from the meta-analysis, the effect size for the MDS-UPDRS Part III (on medication) in endpoints shifted to non-significance, indicating that this study may have had a disproportionate influence on the overall findings (MD = 2.65
